Mr. Rob Fia reports

THERMA BRIGHT ANNOUNCES FOLLOW-ON ORDER FROM HORIZON HEALTH AS VENOWAVE GAINS TRACTION IN U.S. VASCULAR MARKETS

Horizon Health has purchased an additional 100 Venowave units from Therma Bright Inc. This second commercial order follows the rapid deployment and clinical success of the initial 100-unit shipment delivered to Horizon in late March, 2026.

The decision by Horizon Health to double its initial commitment underscores the strong demand for the Venowave mobile compression device within Horizon's extensive vascular patient population. By leveraging Horizon's established distribution channels, the technology has reached patients requiring effective, mobile solutions for circulation and DVT (deep vein thrombosis) prevention with seamless integration.

Rob Fia, chief executive officer of Therma Bright commented: "Seeing Horizon Health return so quickly for a second order validates our belief that Venowave is a superior solution for vascular patients. This follow-on purchase confirms that our distribution strategy is working, and we are now focused on supporting Horizon as they continue to scale these volumes across their network."

Steve Ebner, co-chief executive officer of Horizon Health, commented: "The feedback from our distribution channels for the first 100 Venowave units has been exceptional. Our clinical teams and patients have reported high satisfaction with the device's performance and ease of use."

James Stadler co-chief executive officer of Horizon Health, commented: "The initial success we've seen with our vascular patient base has been a primary driver for this second order. Based on the positive outcomes and the efficiency of our current distribution channels, we anticipate a potential ramp-up in order frequency and volume as we move through the remainder of the year."

Commercial outlook

With Horizon Health currently moving over 35,000 compression products annually, Therma Bright views these consecutive 100-unit orders as the foundation for a significant long-term revenue stream. Both companies are working closely to monitor patient outcomes and supply chain efficiency to support a projected increase in order sizes as Venowave becomes a staple in Horizon's vascular care protocols.

About Venowave

Venowave is a compact, battery-operated peristaltic pump that is worn on the calf. It is designed to increase blood flow in the veins to prevent blood clots and treat symptoms of chronic venous insufficiency. Venowave is a mobile mechanical compression system reimbursable in the United States through Medicare with permanent HCPCS Code E0683.

About Therma Bright Inc.

Therma Bright is a developer and investment partner specializing in advanced diagnostic and medical device technologies. The company's portfolio includes innovative solutions for vascular health, respiratory diagnostics and topical treatments. Therma Bright is listed on the TSX Venture Exchange (symbbol: THRM), the OTCQB market (symbol: TBRIF) and the Frankfurt Stock Exchange (suyol: JNX0).

We seek Safe Harbor.